TAYYAB PARACHA: Open Payments
NPI 1629211008 · LEESBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,012 in 44 payments from 9 companies in 2025. Trend: 2023 $391 · 2024 $1,105 · 2025 $1,012
Food & beverage: $902Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $231 |
| Neurocrine BioSciences, Inc. | 9 | $176 |
| Otsuka America Pharmaceutical, Inc. | 6 | $147 |
| ABBVIE INC. | 6 | $119 |
| Janssen Pharmaceuticals, Inc | 6 | $113 |
| Alkermes, Inc. | 4 | $88 |
| E.R. Squibb & Sons, L.L.C. | 4 | $70 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
Products named: INGREZZA, VRAYLAR, INVEGA SUSTENNA, ABILIFY ASIMTUFII, ARISTADA, COBENFY, UZEDY, AUSTEDO XR.
Industry payments across VA — which companies pay providers there.
